Stevanato Group SpA

Stevanato Group SpA engages in the provision of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It operates through the following segments: Biopharmaceutical and Diagnostic Solutions, and Engineering segments. The Biopharmaceutical and Diagnostic Solutions segment includes all the products, processes, and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. The Engineering segment deals with all the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology and diagnostic manufacturing processes. The company was founded by Giovanni Stevanato in 1949 and is headquartered in Piombino Dese, Italy.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stevanato Group excels in 2022, eyes high value solutions growth

Stevanato Group's strong financial performance in 2022, driven by high value solutions and operational efficiency, sets a solid foundation for future growth.
Strategic focus on biologics and high growth markets, along with optimized capital spending, positions the company for long-term success.
Challenges in pricing management and capacity ramp-up require careful navigation, while opportunities in expanding high value solutions and market demand offer avenues for growth.
Overall, Stevanato Group's performance reflects resilience, strategic foresight, and a commitment to value creation, signaling a positive trajectory for the company.

Stevanato Group reports strong Q1 results, eyes biologics market growth

Stevanato Group's Q1 performance reflects robust revenue growth, profitability, and a strong order backlog, underpinned by strategic collaborations and market focus.
While facing challenges such as pricing pressures and market dynamics, the company is well-positioned to leverage opportunities in the biologics sector and innovative drug delivery solutions.
With a reiterated full-year revenue guidance and a focus on operational excellence, Stevanato Group demonstrates resilience and strategic foresight in navigating the evolving healthcare landscape.
Investors can find confidence in the company's performance, strategic strengths, and growth opportunities amidst the challenges and uncertainties in the market.

Stevanato Group SpA reports robust Q2 performance and eyes growth

Stevanato Group SpA's Q2 2023 earnings call highlighted strong performance, growth prospects, and strategic initiatives amidst market challenges.
The company's financial results, revenue breakdown, and guidance underscore its resilience and potential for sustained growth.
Addressing challenges like currency fluctuations and market dynamics while seizing growth opportunities will be key for Stevanato Group SpA's future success.

Stevanato Group reports strong Q3 earnings, eyes biologics market growth

Stevanato Group's Q3 2023 performance showcased robust revenue growth and margin expansion, despite challenges in specific segments. The company's strong presence in key biologics markets and strategic priorities for sustainable growth position it well for the future. Opportunities in expanding markets and a solid order backlog provide a positive outlook.

Stevanato Group reports 10% revenue growth in Q4 2023

Stevanato Group's 2023 performance reflects growth driven by high-value solutions and strong demand.
Despite challenges like margin pressure and supply chain issues, the company remains confident in achieving growth.
Opportunities lie in expanding capacity, enhancing product mix, and capitalizing on backlog growth.
The company anticipates a stronger second half of 2024 and foresees material revenue impact from biologic products in 2025.

Stevanato Group faces Q1 challenges, invests in growth opportunities

Stevanato Group's Q1 2024 performance was impacted by industry-wide challenges, but the company remains focused on strategic priorities and operational efficiencies.
Despite revenue decline and margin impacts, the company's commitment to growth through expansion projects and high-value solutions showcases resilience and forward-thinking.
Challenges in vial demand and customer delays are being addressed through cost management and strategic actions, while opportunities in new investments and operational focus are being pursued.
The company's leadership position, solid strategy, and emphasis on execution position Stevanato Group for long-term success despite near-term headwinds.

Stevanato Group reports modest revenue growth amidst margin challenges

Stevanato Group delivered mixed results in Q2, with revenue growth driven by the Biopharmaceutical and Diagnostic Solutions segment.
While facing margin pressures and operational challenges, the company's focus on high-value solutions and efficiency improvements bodes well for long-term prospects.
Navigating through current obstacles, Stevanato Group remains optimistic about its ability to drive growth and enhance profitability.

Stevanato Group adjusts guidance amidst challenges, eyes growth opportunities

Stevanato Group's Q3 2024 performance was impacted by challenges in Engineering and the U.S., leading to a revised full-year guidance.
Despite operational challenges, the company demonstrated strengths in capacity expansion, innovation, and revenue growth.
Addressing challenges in vial destocking and segment optimization presents opportunities for future growth and profitability.
Analyst questions highlighted the need to navigate current challenges while capitalizing on opportunities for strategic advancement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, NY / ACCESSWIRE / July 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.

STVN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Stevanato Group S.p.A. investment

NEW YORK, NY / ACCESSWIRE / July 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.

Investors who lost money on Stevanato Group S.p.A. should contact Levi & Korsinsky about an ongoing investigation - STVN

NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.

Stevanato Group S.p.A. (STVN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights

NEW YORK, NY / ACCESSWIRE / July 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.

STVN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Stevanato Group S.p.A. Investment

NEW YORK, NY / ACCESSWIRE / July 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.

Stevanato Being Investigated on Behalf of Stevanato Group S.p.A. Investors.

NEW YORK, NY / ACCESSWIRE / June 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.

Stevanato Group S.p.A. (STVN) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates

NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.

An Investigation Has Commenced on Behalf of Stevanato Group S.p.A. Shareholders.

NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.

Shareholder Rights Advocates at Levi & Korsinsky Investigate Stevanato Group S.p.A. (STVN) Regarding Possible Securities Fraud Violations

NEW YORK, NY / ACCESSWIRE / June 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.

Lost Money on Stevanato Group S.p.A.(STVN)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / June 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Stevanato Group S.p.A. ("Stevanato") (NYSE:STVN) concerning possible violations of federal securities laws.

Stevanato Group S.p.A. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- STVN

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life science industries, today announced the inauguration of its Cisterna di Latina plant. Located just a few kilometers from the Group's first historic plant in Latina, the new site covers an area of 65,000 square meters and employs around 200 people. The facility started commercial production.

Stevanato Group Unveils New Plant in Cisterna di Latina for the Production of Pre-Sterilized EZ-fill® Syringes and Cartridges

Stevanato revised its guidance for 2024 due to weaker-than-expected orders and clients' destocking activities. The company's Q1 results show decreased EBITDA and profit, causing investors to sell off shares. Here at the Lab, we remain confident in long-term prospects thanks to capacity expansion and biologics demand.

Stevanato: Destock Pressures, Long-Term Upside

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that its Board of Directors has appointed Franco Stevanato, a current director and the Executive Chairman of the Company, as its new Chief Executive Officer. Mr. Stevanato is succeeding as Chief Executive Officer Franco Moro, whose employment agreement w.

Stevanato Group Appoints Franco Stevanato Chief Executive Officer, Succeeding Franco Moro

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries today announced that all resolutions proposed to the Shareholders at the Annual General Meeting of Shareholders (“AGM”) held virtually on May 22, 2024, have passed. Details of the resolutions submitted to, and approved by, the AGM are included in the explanatory report p.

Stevanato Group Announces Results of Annual General Meeting

USANA Health Sciences

Investors with an interest in Medical - Drugs stocks have likely encountered both USANA Health Sciences (USNA) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now?

USNA vs. STVN: Which Stock Should Value Investors Buy Now?

Stevanato Group S.p.A. (NYSE:STVN ) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Lisa Miles – Investor Relations Franco Stevanato – Executive Chairman Marco Dal Lago – Chief Financial Officer Franco Moro – Chief Executive Officer Conference Call Participants Michael Ryskin – Bank of America Paul Knight – KeyBanc Patrick Donnelly – Citi Sam Martin – William Blair Tucker Remmers – Jefferies Curtis Moiles – BNP Paribas Exane Lisa Miles Good morning, and thanks for joining us.

Stevanato Group S.p.A. (STVN) Q1 2024 Earnings Call Transcript

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2024. First Quarter 2024 Highlights Revenue for the first quarter of 2024 decreased 1% to €236.0 million compared with the same period last year, and high-value solutions represented 37% of total revenue.

Stevanato Group Reports Financial Results for the First Quarter of 2024

Investors interested in stocks from the Medical - Drugs sector have probably already heard of USANA Health Sciences (USNA) and Stevanato Group (STVN). But which of these two companies is the best option for those looking for undervalued stocks?

USNA or STVN: Which Is the Better Value Stock Right Now?

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the Bank of America Securities Healthcare Conference taking place from Tuesday, May 14, 2024 to Thursday, May 16, 2024. The Company will present on Wednesday, May 15, 2024 at 11:20 a.m. (PT). A live webcast will be available.

Stevanato Group to Present at the Bank of America Securities Healthcare Conference

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2024 on Thursday, May 9, 2024, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, May 9, 2024, to discuss fina.

Stevanato Group to Report First Quarter 2024 Financial Results on May 9, 2024

Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Stevanato Group (STVN) to Report Q1 Results: What You Should Expect

Catalent

DexCom

Eli Lilly

Novo Nordisk

The diabetes and obesity markets are large and growing, with an estimated total long-term addressable market of $100 billion in the US alone. Denmark's Novo Nordisk and US-based Eli Lilly are leading pharmaceutical companies in the development of GLP-1-based treatments for diabetes and obesity.

International Companies Drive Diabesity Innovation

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the closing of its previously announced upsized underwritten public offering of an aggregate of 14,605,000 of its ordinary shares, which includes the full exercise of the underwriters' option to purchase 1,905,000 ad.

Stevanato Group Announces Closing of Upsized Public Offering of Ordinary Shares and Exercise in Full of the Underwriters' Option to Purchase Additional Ordinary Shares

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the pricing of its upsized underwritten public offering of an aggregate of 12,700,000 of its ordinary shares at a public offering price of $26.00 per share. Stevanato Group is offering 6,350,000 ordinary shares (the.

Stevanato Group Announces Pricing of Upsized Public Offering of Ordinary Shares

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the launch of an underwritten public offering of an aggregate of $300,000,000 of its ordinary shares. Stevanato Group is offering $150,000,000 of its ordinary shares (the “Company Offering”), and Stevanato Holding S.

News for Stevanato Group SpA Stock (STVN)